Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,308
  • Shares Outstanding, K 2,127
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,580 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.82
  • Most Recent Earnings $-1.03 on 05/14/25
  • Next Earnings Date 08/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5980 +2.81%
on 07/17/25
1.3300 -53.77%
on 06/20/25
-0.4652 (-43.07%)
since 06/18/25
3-Month
0.5980 +2.81%
on 07/17/25
1.3300 -53.77%
on 06/20/25
-0.0622 (-9.19%)
since 04/17/25
52-Week
0.4519 +36.05%
on 04/09/25
7.2000 -91.46%
on 01/13/25
-1.8202 (-74.75%)
since 07/18/24

Most Recent Stories

More News
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock...

SLRX : 0.6148 (+0.26%)
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

SLRX : 0.6148 (+0.26%)
Salarius: Q1 Earnings Snapshot

Salarius: Q1 Earnings Snapshot

SLRX : 0.6148 (+0.26%)
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

SLRX : 0.6148 (+0.26%)
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

SLRX : 0.6148 (+0.26%)
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

SLRX : 0.6148 (+0.26%)
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

SLRX : 0.6148 (+0.26%)
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

SLRX : 0.6148 (+0.26%)
Salarius: Q3 Earnings Snapshot

Salarius: Q3 Earnings Snapshot

SLRX : 0.6148 (+0.26%)
Salarius: Q2 Earnings Snapshot

Salarius: Q2 Earnings Snapshot

SLRX : 0.6148 (+0.26%)

Business Summary

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and...

See More

Key Turning Points

3rd Resistance Point 0.6780
2nd Resistance Point 0.6635
1st Resistance Point 0.6391
Last Price 0.6148
1st Support Level 0.6002
2nd Support Level 0.5857
3rd Support Level 0.5613

See More

52-Week High 7.2000
Fibonacci 61.8% 4.6222
Fibonacci 50% 3.8259
Fibonacci 38.2% 3.0297
Last Price 0.6148
52-Week Low 0.4519

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar